For a person navigating a cancer diagnosis, the most pressing question in a doctor’s office is rarely the most important one. It is the logistical and emotional weight of the rest of life,transportation, food insecurity, financial strain, mental health,that often determines whether a treatment plan succeeds. Patient Discovery, a Newton-based startup founded in 2016, is building its entire business on the premise that systematically capturing and acting on these non-medical factors is not just good care, but a critical, billable part of the clinical workflow [Patient Discovery, 2024].
A workflow wedge for whole-person care
The company’s core product, the Patient Discovery Platform (also branded as Companion), is a software layer designed to sit within an oncology practice. It collects patient-reported data on social determinants of health and other barriers before and between appointments, then centralizes that information into structured tasks for the entire care team, including non-clinical staff [Patient Discovery, 2024]. The bet is that by giving clinicians and coordinators a unified view of a patient’s holistic needs, the platform can improve care coordination, boost appointment productivity, and help practices capture reimbursements tied to addressing health equity [PitchBook, 2024].
The team betting on a boardroom heavyweight
Founder and CEO Norm Shore, a healthcare technology entrepreneur and former CFO of True Office, started the company driven by personal experiences as a caregiver [Clinical Pathways Congress, 2026]. While details on the other two co-founders are not public, the company has made a significant governance hire, bringing Sandra Fenwick, the former CEO of Boston Children’s Hospital, onto its board of directors [PR Newswire, 2022]. This move signals an ambition to navigate the complexities of large health systems, a customer segment Patient Discovery explicitly targets alongside oncology practices and life sciences companies [Patient Discovery, 2024].
| Role | Name | Notable Background |
|---|---|---|
| Co-Founder & CEO | Norm Shore | Healthcare technology entrepreneur, former CFO of True Office [Clinical Pathways Congress, 2026] |
| Chief Technology Officer | Julie Stern | Not specified in public sources [Crunchbase, 2024] |
| VP Health Solutions | Robyn Hayes | Formerly at Johnson & Johnson Innovative Medicine [LinkedIn, 2026] |
| Board Director | Sandra Fenwick | Former CEO, Boston Children’s Hospital [PR Newswire, 2022] |
Funding a long-term play in a cautious market
Patient Discovery has raised an estimated $8.35 million across several rounds since its 2017 seed, with a $2 million Series A closed in April 2025 [PitchBook, 2024]. The funding history, while not massive by biotech standards, suggests a capital-efficient SaaS approach focused on product development and early commercial traction in a niche that has only recently gained widespread regulatory and payer attention.
2017 Seed | 3.6 | M USD
2019 Early Stage VC | (part of total) | M USD
2025 Series A | 2.0 | M USD
The risks in a crowded adjacency
The company’s focus is its sharpest differentiator, but also its primary challenge. The market for digital patient engagement and care coordination is dense with well-funded competitors, from large EHR vendors to specialty point solutions. Patient Discovery’s success hinges on proving that its oncology-specific workflow for social determinants delivers tangible ROI where broader platforms fall short. The risks are not trivial:
- Proof of value. The platform must demonstrate it moves the needle on hard outcomes like reduced no-show rates, improved patient satisfaction scores, or increased reimbursement capture from payers who value SDoH interventions.
- Integration depth. smooth integration with existing electronic health records is a non-negotiable for busy clinical teams; any friction in workflow could sink adoption.
- Sales motion. Convincing cash-strapped oncology practices to invest in yet another software layer requires a compelling cost-benefit argument that may be easier to make to larger health systems or life science partners funding patient support programs.
For the roughly 1.9 million Americans diagnosed with cancer each year, the standard of care today is a fractured experience. Clinical encounters focus on the disease, while the crushing weight of logistics, finances, and isolation is managed ad-hoc, if at all. It creates a system where the best medical advice can be rendered useless by a lack of a ride or an overwhelming stack of bills. Patient Discovery is betting that by making those invisible burdens visible and actionable, it can help rewrite that story for patients and the practices that treat them.
Sources
- [Patient Discovery, 2024] How we help | https://www.patientdiscovery.com/how
- [PitchBook, 2024] Patient Discovery 2026 Company Profile | https://pitchbook.com/profiles/company/170290-54
- [PR Newswire, 2022] Sandra Fenwick Joins Patient Discovery's Board of Directors | https://www.prnewswire.com/news-releases/sandra-fenwick-joins-patient-discoverys-board-of-directors-301459987.html
- [Crunchbase, 2024] Patient Discovery Solutions - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/patient-discovery-solutions
- [LinkedIn, 2026] Robyn Hayes - Johnson & Johnson Innovative Medicine | https://www.linkedin.com/in/robyn-hayes-a5a07b7/